Rwanda confirmed its first-ever Marburg virus outbreak in September 2024. By the time it was contained, 66 people had been infected and 15 had died — a 23% case fatality rate. PandemicAlarm rated the event at severity 4/5 based on the virus's high lethality, its novelty for Rwanda, and the outbreak's concentration among healthcare workers. The outbreak is now contained, but it exposed vulnerabilities that haven't gone away.
Marburg virus belongs to the same family as Ebola. It kills through the same mechanism: progressive hemorrhagic fever that destroys blood vessels and organ tissue. No approved vaccine exists. No specific antiviral treatment is available. When Marburg appears, the response relies on isolation, contact tracing, and infection prevention, the same tools public health has used against hemorrhagic fevers for decades.
How did Rwanda's outbreak unfold?
The first confirmed cases were healthcare workers at hospitals in Kigali. Marburg's early symptoms (fever, severe headache, muscle pain) mimic many common infections, and initial patients were treated for other conditions before Marburg was identified. By the time laboratory confirmation came back, nosocomial transmission chains were already active.
Healthcare workers accounted for a disproportionate share of total cases. Direct contact with blood, vomit, and other bodily fluids during patient care is the primary transmission route, and standard infection control precautions weren't implemented until after the virus was identified. Rwanda's health system responded quickly once the diagnosis was made: cases were isolated, contacts traced, and infection prevention and control measures scaled up across Kigali's hospitals.
International assistance arrived within days. WHO deployed experts and supplies. Experimental vaccines from the Sabin Vaccine Institute were offered to frontline healthcare workers and high-risk contacts under a compassionate use framework. Rwanda's prior experience managing infectious disease outbreaks, and its healthcare infrastructure (among the strongest in East Africa), contributed to relatively rapid containment.
Rwanda declared the outbreak over in December 2024 after 42 days with no new cases (two maximum incubation periods for Marburg). Surveillance continues.
What is Marburg virus?
Marburg virus is a filovirus, the same family that includes all Ebola virus species. First identified in 1967 when laboratory workers in Marburg and Frankfurt, Germany, and in Belgrade, Yugoslavia, fell ill after handling tissues from African green monkeys imported from Uganda. 31 people were infected; 7 died.
Since then, outbreaks have been sporadic but severe. Angola's 2004-2005 outbreak was the deadliest: 252 cases with a 90% case fatality rate. The Democratic Republic of Congo, Uganda, and Ghana have also experienced outbreaks. Most were small (fewer than 20 cases), but the Angola outbreak demonstrated what happens when Marburg reaches a setting with limited infection control.
Historical CFR for Marburg ranges from 23% to 90%, with the variation driven almost entirely by healthcare access. Rwanda's 23% rate reflects a well-functioning health system that provided supportive care rapidly. In settings without IV fluid resuscitation, intensive monitoring, and strict isolation capacity, the fatality rate climbs steeply.
Where does the virus come from?
Egyptian fruit bats (Rousettus aegyptiacus) are the known natural reservoir. These bats carry Marburg virus without becoming visibly ill and shed it in their saliva and excrement. Humans typically acquire initial infections through prolonged exposure in bat-inhabited caves or mines.
Uganda's Kitaka mine and Python Cave have both been linked to Marburg spillover events. Miners and tourists entering bat caves face the highest risk of primary zoonotic transmission. Once a human is infected, the virus spreads person-to-person through direct contact with blood, secretions, and other bodily fluids, or through contact with contaminated surfaces and materials like bedding.
Marburg does not spread through airborne transmission under normal conditions. This limits its pandemic potential compared to respiratory pathogens — you won't catch Marburg by sitting on a bus with an infected person. But in healthcare settings where clinicians handle patient fluids without adequate personal protective equipment, transmission can be rapid and devastating.
Why did PandemicAlarm rate this 4/5?
Four factors drove the severity rating.
High case fatality rate. Even at 23%, Marburg kills roughly 1 in 4 confirmed patients. Compare that to COVID-19's IFR of approximately 0.5-1.0% or seasonal influenza at around 0.1%. Marburg is in a different category of lethality.
No approved countermeasures. Without a licensed vaccine or antiviral, every response depends on containment measures that must be implemented perfectly to work. One gap in infection control at one hospital can restart transmission chains.
Healthcare system impact. When healthcare workers are disproportionately affected, as they were in Rwanda, the outbreak doesn't just kill patients directly. It degrades the capacity to treat everyone else. Hospitals lose staff. Remaining workers operate under extreme psychological pressure. Routine medical care suffers.
Novel for the region. Rwanda had never experienced Marburg before. First-time outbreaks in a new country carry higher risk because clinicians lack experience recognizing the disease, laboratory protocols may not be optimized for rapid confirmation, and public awareness is low. Rwanda handled it well. A country with weaker infrastructure might not.
PandemicAlarm did not rate this 5/5 because Marburg's transmission characteristics limit its pandemic potential. Person-to-person spread requires direct fluid contact, not airborne droplets. Containment, while difficult, is achievable with standard public health measures applied rigorously.
What happens next?
Rwanda's outbreak is contained. But Egyptian fruit bats range across sub-Saharan Africa, and the conditions that enabled spillover in Rwanda exist in dozens of other countries. Tanzania confirmed a small Marburg outbreak in early 2023. Equatorial Guinea experienced its first outbreak in February 2023. The frequency of Marburg spillover events appears to be increasing, though whether that reflects true acceleration or improved detection remains debated.
Vaccine development is the most significant development to watch. The Sabin Vaccine Institute's cAd3-Marburg vaccine showed promising results in early-phase trials and was used under compassionate access in Rwanda. If phase 3 trials succeed and production scales up, it would fundamentally change the risk profile for future outbreaks. Until then, Marburg remains a virus with no medical countermeasure beyond supportive care.
For PandemicAlarm users, Marburg events will continue to receive high severity scores whenever they appear. Monitor the map and check the disease severity scoring methodology to understand how we weight lethality, novelty, and healthcare system impact. If you work in healthcare in sub-Saharan Africa or travel to regions with known bat cave exposure risks, understand the symptoms: sudden fever, severe headache, and malaise progressing to hemorrhagic manifestations within a week.
Early detection saves lives with Marburg. Not because treatment exists, but because isolation prevents the next case.